With the UK Supreme Court now considering its judgment on the future approach to second medical use patents in the UK, I am very much looking forward to hearing what @Juergen Dressel, Head of Global Patent Strategy at Novartis, has to say on the patentability and enforcement of such patents from his perspective at the C5 Life Sciences Conference in Amsterdam on 27th Feburary. For those interested, a recording of the arguments @Warner-Lambert and @Mylan as made to the UK Supreme Court in the pregabalin patent case can be found here.
| less than a minute read
An insight into second medical use patents
This week our Life Sciences team published the first edition of its Cross-border Guide to Clinical Trials and Privacy. The Guide will...